ClinicalTrials.gg
Not yet recruitingNCT07658378Updated Jun 24, 2026

Continuous Infusion Versus Intermittent IV Bolus of Cefazolin: Prevention of Surgical Site Infection During CABG Surgeries in Egyptian Patients.

A Phase 4 interventional study of Cefazolin 2 g Infusion and Cefazolin 2 GM Injection in Surgical Site Infection (SSI), sponsored by Helwan University. Not yet recruiting. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-06-24.

Sponsored by Helwan University · Phase 4, Interventional, and Prevention

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 4
Study type
Interventional
Enrollment
100
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 18 studies testing cefazolin in Surgical Wound Infection — 4 open to participants now, 5 under way, 2 of them phase 3. Cefazolin · Surgical Wound Infection.

Planned enrollment
13th of 18
100 · median 180
Started
2026
with 2 others
Phase 4
8 of 18
3 open now
Registered
16th of 18
by date
Lead sponsor
2 of 18
Helwan University

Among the 18 studies testing cefazolin in Surgical Wound Infection, this one is the 13th largest by planned enrollment, is one of 3 that started in 2026, is one of 8 in phase 4, and was the 16th registered.

Surgical Wound Infection

747 studies on the registry are indexed under Surgical Wound Infection; 152 are open to participants now.

Browse Surgical Wound Infection studies →

Open to participants now

4 of the 18 studies testing cefazolin in Surgical Wound Infection are open now, in 6 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 4 open studies →

About cefazolin

Cefazolin: first FDA approval 1973 (ANCEF). What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 85 Surgical Wound Infection studies recruiting now, 62 (73%) set no upper age limit and 16 (19%) stop at 75 or younger; 12 take children under 18; 14 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 18 studies testing cefazolin in Surgical Wound Infection, or all of them as a file.
02

Study summary

A randomized controlled trial on adults who underwent coronary artery bypass grafting (CABG) surgery. To evaluate the effectiveness of intraoperative continuous infusion (CI) of cefazolin compared with intermittent (INT) cefazolin administration in preventing surgical site infection in the CABG population.

Eligible patients will be randomized using a block design into 2 groups: intervention and control. The intervention group will use continuous infusion of cefazolin (CI), while the control group will follow the traditional presurgical prophylaxis protocol of intermittent cefazolin doses (INT).

03

Conditions studied

  • Surgical Site Infection (SSI)

Keywords

  • cefazolin
  • continuous infusion
  • intermittent
  • surgical site infection
  • surgical prophylaxis
  • CABG
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Cardiothoracic ICU-admitted patients who underwent CABG on CPB.

Exclusion criteria

Exclusion Criteria:

  • Patients who require reoperation within 30 days.
  • patients.
  • Patients who are not adherent to the protocol time or dosing, either preoperatively, during, or postoperatively.
  • Pregnancy or breastfeeding.
  • Patients who refused to sign the .
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

05

Study design

Phase
Phase 4
Primary purpose
Prevention
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Single (Outcomes assessor)
Enrollment
100 participants (estimated)

Study arms

  • Experimental
    Intraoperative continuous infusion (CI) of cefazolin

    Drug: Cefazolin 2 g Infusion

  • Active comparator
    Intermittent (INT) cefazolin

    Drug: Cefazolin 2 GM Injection

Interventions

  • DrugCefazolinStudies of CefazolinCefazolin pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record.

    To evaluate the effectiveness of intraoperative continuous infusion (CI) of cefazolin compared with intermittent (INT) cefazolin administration in preventing SSIs in a CABG (coronary artery bypass grafting) population.

  • DrugCefazolin 2 GM Injection

    To evaluate the effectiveness of intermittent (INT) cefazolin administration in preventing SSIs in a CABG (coronary artery bypass grafting) population.

06

What researchers measure

Primary outcomes

  1. Incidence of SSI

    Time frame: Within 3 months after surgery

07

Study locations

No study locations are listed for this record.

08

References and documents

Individual participant data

Plan to share: Undecided

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Start is estimated for Jul 2026; primary completion for Sep 2026, 2 months later.

Of 45 non-industry phase 4 interventional studies under Surgical Wound Infection, half reached primary completion within 31 months of starting (the median), counting those still running; a quarter within 16 and three quarters within 51. This study's planned 2 months is below that.

Counting every sponsor, half of 47 studies reached it within 30 months; a quarter within 16 and three quarters within 51.

How these figures are worked out, and which studies are left out of them.

Registered
Jun 13, 2026
First posted
Jun 22, 2026
StartEst.
Jul 1, 2026
Primary completionEst.
Sep 30, 2026
CompletionEst.
Dec 31, 2026
Last update
Jun 24, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jun 24, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07658378
Lead sponsor
Helwan University
Responsible party
Hebatallah Ali Abdeen (Principal Investigator, Helwan University) — Principal investigator
First posted
Jun 22, 2026
Start date
Jul 1, 2026 (estimated)
Primary completion
Sep 30, 2026 (estimated)
Completion
Dec 31, 2026 (estimated)
Last update
Jun 24, 2026

Study contacts

Heba A Abdeen
Contact
hebabdeen89@gmail.com
0201003403231

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Jun 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Cefazolin

Start the discussion